Literature DB >> 24094667

[Chemotherapy in epithelial ovarian cancer].

Y Tazi1, P Pautier, A Leary, C Lhomme.   

Abstract

Chemotherapy is fundamental in the management of epithelial ovarian carcinomas both for early and advanced stages (rarely surgical treatment alone) and in almost every step of the disease. The reference schema combines carboplatin and paclitaxel intravenously. Intraperitoneal chemotherapy also proved its efficacy after complete surgery for advanced disease and should be reserved to trained teams due to its technical constraints and toxicity issues. Modalities of treatment in relapsed and progressive disease depend mainly on the free interval between this diagnosis and the last dose of platinum. Bevacizumab has proven its effectiveness in prolonging progression-free survival in 1st line setting in association with chemotherapy followed by maintenance and in case of relapse or progression both fore platinum sensitive or resistant disease. Finally, a better understanding of ovarian cancer biology will allow us to consider new molecular-targeted agents guided by the specific characteristics of each patient and each tumor.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anti angiogenic; Antiangiogénique; Cancer; Chemotherapy; Chimiothérapie; Ovaire; Ovary; Platine; Platinium; Targeted treatment; Traitement ciblé

Mesh:

Substances:

Year:  2013        PMID: 24094667     DOI: 10.1016/j.gyobfe.2013.08.008

Source DB:  PubMed          Journal:  Gynecol Obstet Fertil        ISSN: 1297-9589


  1 in total

Review 1.  Profile of vintafolide (EC145) and its use in the treatment of platinum-resistant ovarian cancer.

Authors:  Mathieu Luyckx; Raffaella Votino; Jean-Luc Squifflet; Jean-François Baurain
Journal:  Int J Womens Health       Date:  2014-03-31
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.